%0 Journal Article
%T Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody-Drug Conjugates (ADCs).
%A Lindgren ES
%A Yan R
%A Cil O
%A Verkman AS
%A Chan MF
%A Seitzman GD
%A Farooq AV
%A Huppert LA
%A Rugo HS
%A Pohlmann PR
%A Lu J
%A Esserman LJ
%A Pasricha ND
%J Curr Ophthalmol Rep
%V 12
%N 2
%D 2024 Jun
%M 38756824
暂无%R 10.1007/s40135-024-00322-5
%X <B>UNASSIGNED: </B>This study is to highlight the incidence of corneal pseudomicrocysts in FDA-approved antibody-drug conjugates (ADCs), and success of preventive therapies for pseudomicrocysts and related ocular surface adverse events (AEs).<BR><B>UNASSIGNED: </B>ADCs are an emerging class of selective cancer therapies that consist of a potent cytotoxin connected to a monoclonal antibody (mAb) that targets antigens expressed on malignant cells. Currently, there are 11 FDA-approved ADCs with over 164 in clinical trials. Various AEs have been attributed to ADCs, including ocular surface AEs (keratitis/keratopathy, dry eye, conjunctivitis, blurred vision, corneal pseudomicrocysts). While the severity and prevalence of ADC-induced ocular surface AEs are well reported, the reporting of corneal pseudomicrocysts is limited, complicating the development of therapies to prevent or treat ADC-related ocular surface toxicity.<BR><B>UNASSIGNED: </B>Three of 11 FDA-approved ADCs have been implicated with corneal pseudomicrocysts, with incidence ranging from 41 to 100% of patients. Of the six ADCs that reported ocular surface AEs, only three had ocular substudies to investigate the benefit of preventive therapies including topical steroids, vasoconstrictors, and preservative-free lubricants. Current preventive therapies demonstrate limited efficacy at mitigating pseudomicrocysts and other ocular surface AEs.